The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)-A Prospective Multicenter Cohort Study-
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 583
- 试验地点
- 23
研究概览
简要总结
The purpose of this study is to determine the clinically meaningful definition and prevalence of aspirin resistance based on data linking aspirin-dependent laboratory tests to recurrent vascular events in cardiovascular patients taking aspirin.
详细描述
Primary Outcomes: The primary endpoint is the composite outcomes of cerebral infarction, transient ischemic attack, myocardial infarction, unstable angina, percutaneous coronary angiography, thromboembolism, and death caused by cardiovascular disease.
Secondary Outcomes: Platelet aggregation induced by collagen and arachidonic acid, serum thromboxane B2, urine 11-dehydrothromboxane B2, platelet thrombus formation under flow conditions (sub-study only at the National Cardiovascular Center)
The primary objective of this study is to determine the markers for aspirin resistance. To achieve this objective, platelet aggregation, serum thromboxane B2, and urine 11-dehydrothromboxane B2 are measured in patients receiving usual therapeutic doses of aspirin, who experienced acute coronary syndrome, cerebral infarction, or transient ischemic attack occurred in a period between the past 1 month and the past 2 years. This is a multi-center, prospective study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult males or females who met the criteria listed below:
- •Patients who had acute coronary syndrome, cerebral infarction (except cardioembolic stroke), or transient ischemic attack between past 28 days and the past 2 years
- •patients who receive long-term aspirin therapy (at least 28 days)
- •Patients who are >=20 years of age
- •Patients willing and able to give written informed consent
排除标准
- •Malignancy or suspected malignancy
- •Patients who showed platelet counts less than 100,000/uL or more than 450,000/uL
- •Congenital bleeding tendency
- •Patients who receive other antiplatelet drugs or warfarin
- •Patients with atrial fibrillation
- •Patients who received surgical operation or catheter intervention within the past 2 weeks
- •Patients who received anticoagulation drug therapy including heparin ( low-molecular weight heparin) and danaparoid.
- •Patients with more than modified Rankin scale 4
研究者
Toshiyuki Miyata
Director
National Cerebral and Cardiovascular Center, Japan